These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 26667000

  • 1. The Many Neuroprogressive Actions of Tryptophan Catabolites (TRYCATs) that may be Associated with the Pathophysiology of Neuro-Immune Disorders.
    Morris G, Carvalho AF, Anderson G, Galecki P, Maes M.
    Curr Pharm Des; 2016; 22(8):963-77. PubMed ID: 26667000
    [Abstract] [Full Text] [Related]

  • 2. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression.
    Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Apr 29; 35(3):702-21. PubMed ID: 21185346
    [Abstract] [Full Text] [Related]

  • 3. Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression.
    Anderson G, Maes M.
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Apr 05; 42():5-19. PubMed ID: 22800757
    [Abstract] [Full Text] [Related]

  • 4. Deficit Schizophrenia Is Characterized by Defects in IgM-Mediated Responses to Tryptophan Catabolites (TRYCATs): a Paradigm Shift Towards Defects in Natural Self-Regulatory Immune Responses Coupled with Mucosa-Derived TRYCAT Pathway Activation.
    Kanchanatawan B, Sirivichayakul S, Ruxrungtham K, Carvalho AF, Geffard M, Anderson G, Maes M.
    Mol Neurobiol; 2018 Mar 05; 55(3):2214-2226. PubMed ID: 28290151
    [Abstract] [Full Text] [Related]

  • 5. The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation.
    Maes M, Mihaylova I, Ruyter MD, Kubera M, Bosmans E.
    Neuro Endocrinol Lett; 2007 Dec 05; 28(6):826-31. PubMed ID: 18063923
    [Abstract] [Full Text] [Related]

  • 6. Overlapping the Tryptophan Catabolite (TRYCAT) and Melatoninergic Pathways in Alzheimer's Disease.
    Maes M, Anderson G.
    Curr Pharm Des; 2016 Dec 05; 22(8):1074-85. PubMed ID: 25547097
    [Abstract] [Full Text] [Related]

  • 7. Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid.
    Kanchanatawan B, Sirivichayakul S, Ruxrungtham K, Carvalho AF, Geffard M, Ormstad H, Anderson G, Maes M.
    Mol Neurobiol; 2018 Feb 05; 55(2):1524-1536. PubMed ID: 28181189
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. IgA/IgM responses to tryptophan and tryptophan catabolites (TRYCATs) are differently associated with prenatal depression, physio-somatic symptoms at the end of term and premenstrual syndrome.
    Roomruangwong C, Kanchanatawan B, Sirivichayakul S, Anderson G, Carvalho AF, Duleu S, Geffard M, Maes M.
    Mol Neurobiol; 2017 May 05; 54(4):3038-3049. PubMed ID: 27037573
    [Abstract] [Full Text] [Related]

  • 11. A New Schizophrenia Model: Immune Activation is Associated with the Induction of Different Neurotoxic Products which Together Determine Memory Impairments and Schizophrenia Symptom Dimensions.
    Sirivichayakul S, Kanchanatawan B, Thika S, Carvalho AF, Maes M.
    CNS Neurol Disord Drug Targets; 2019 May 05; 18(2):124-140. PubMed ID: 30451122
    [Abstract] [Full Text] [Related]

  • 12. Bipolar Disorder: The Role of the Kynurenine and Melatonergic Pathways.
    Anderson G, Jacob A, Bellivier F, Geoffroy PA.
    Curr Pharm Des; 2016 May 05; 22(8):987-1012. PubMed ID: 26654772
    [Abstract] [Full Text] [Related]

  • 13. Physio-somatic symptoms in schizophrenia: association with depression, anxiety, neurocognitive deficits and the tryptophan catabolite pathway.
    Kanchanatawan B, Sirivichayakul S, Thika S, Ruxrungtham K, Carvalho AF, Geffard M, Anderson G, Noto C, Ivanova R, Maes M.
    Metab Brain Dis; 2017 Aug 05; 32(4):1003-1016. PubMed ID: 28258445
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
    Sas K, Robotka H, Toldi J, Vécsei L.
    J Neurol Sci; 2007 Jun 15; 257(1-2):221-39. PubMed ID: 17462670
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis.
    Myint AM, Kim YK.
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan 03; 48():304-13. PubMed ID: 24184687
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.